Sunday, January 6, 2013

Polio

Happy New Year!



Christmas this year was bittersweet. It was Andrew's first Christmas and our first Christmas without my mother-in-law Mary. Holly and I also became homeowners last month, although next Christmas will be our first in our new home.


At his 2 month visit in September, Andrew received Pentacel® (diphtheria, tetanus, acellular pertussis, Hib, IPV) instead of Pediarix®. The Pediarix® he received this visit won't count as Andrew's third and final dose of hepatitis B vaccine, but it saved him an extra poke, since he would have had to have received separate DTaP and IPV shots (Kinrix®, a combination DTaP and IPV vaccine is licensed for children 4 to 6 years of age).

Poliomyelitis

Asymmetric weakness:
The muscles in this man's right
leg are atrophied while his left
leg appears normal.
CDC/NIP/Barbara Rice
The word poliomyelitis means "inflammation of gray marrow" (Greek: polios, gray, + myelos, marrow, + -itis, inflammation) because the poliovirus destroys nerve cells (gray matter) in the spinal cord which transmit impulses from the brain to the muscles. Damage to these cells causes muscle weakness and
paralysis. The virus also destroys nerve cells in the brain. It rarely causes sensory loss.

Paralytic polio typically causes weakness in limb muscles that is greater on one side of the body (asymmetric). Polio can paralyze the diaphragm and muscles in the chest, leaving a person unable to breathe. An "iron lung" is a negative pressure ventilator used to keep people with paralysis of the respiratory muscles alive.

Mr. Barton Hebert used this iron lung from the late 1950s until his death in 2003
CDC
Poliovirus is transmitted by the fecal-oral route, which means that the virus is shed in the stool of an infected person and then taken into the mouth with contaminated food, water, or other objects, such as fingers that have touched contaminated surfaces. The virus replicates in the back of the throat (oropharynx) and the intestine and then spreads into the blood (viremia).

Less than 1% of people infected with poliovirus develop paralytic polio. More commonly, infected people develop a minor illness called abortive polio: fever, nausea, vomiting, headache, sore throat, fatigue, and malaise with no neurological abnormalities. A small proportion will develop nonparalytic polio (viral meningitis) or polioencephalitis.

Over 95% of people infected with poliovirus have no symptoms yet still shed the virus and can infect others. Therefore, reported cases of paralytic polio are only the tip of the iceberg of total poliovirus infections.

My great aunt Gertie had polio
as a child. She could walk
using her hands to move her
feet
Polio was declared eliminated from the U.S. in 1979 and certified eliminated from the WHO Region of Americas in 1994. Today, most parents of infants and most doctors in the U.S. have never seen a case of polio. I had a great aunt who had polio as a child. I've seen a few adults in this country with post-polio syndrome, and I've seen children in Africa with atrophied limbs from polio, but I've never seen an acute case of polio. It's easy to forget how terrifying polio was in the pre-vaccine era.

We usually think of improvements in sanitation as reducing the burden of disease. The opposite occurred with polio in the United States. Polio had been an infection that was usually acquired in infancy. Because the infection occurred at a time when babies were still protected by antibodies they received from their mothers while in the womb (passive immunity), few babies developed polio. As sanitation improved, babies were no longer exposed to poliovirus and did not develop their own antibodies to the virus. Children were exposed to poliovirus after they were no longer protected by maternal antibodies and epidemics began to occur.

During the 1916 polio epidemic in New York City over 9,000 people were paralyzed and 2,343 people died from the disease, most of them young children. Police guarded the entrances to nearby Hoboken, New Jersey to prevent people from New York from entering that city. Polio epidemics in the United States increased in size through the first half of the 20th century. In 1952 there were 57,879 cases of polio reported in the U.S. After the introduction of the Salk polio vaccine in 1955, the incidence of polio in the U.S. decreased from 25 cases per 100,000 people every year to 0.4 cases per 100,000 in 1962.

The history of the development of the Salk inactivated polio vaccine and Sabin live oral polio vaccine has been well-documented in books and in the media. I won't go into the details here, but I've included some links to websites below for those who are interested and also recommend Paul Offit's book The Cutter Incident.

Polio vaccines

There are two types of polio vaccines used today, inactivated poliovirus vaccine (IPV) and oral poliovirus vaccine (OPV). IPV is a killed-virus vaccine that was developed by Jonas Salk and licensed for use in the U.S. in 1955. IPV is currently the only polio vaccine used in the U.S. It is administered by injection and is both highly effective and safe.

Oral poliovirus vaccine contains live attenuated (weakened) poliovirus. Because the vaccine virus replicates in the throat and in the intestine, it causes a better production of immunoglobulin A (IgA), an antibody found on mucosal surfaces, than IPV. Vaccine virus is also shed in stool and can be transferred to close contacts of vaccine recipients. OPV was used in the U.S. from the early 1960s until the late 1990s.

Administering OPV in Gorakhpur, India
CDC/Chris Zahniser
OPV is highly effective, inexpensive, and can be administered by non-medical personnel. There is also a 1 in 2.4 million dose risk of vaccine-associated paralytic polio (VAPP). There were 144 cases of VAPP in the U.S. between 1980 and 1998. Because the risk of VAPP outweighed the risk of wild poliovirus infection in the U.S., the CDC's Advisory Committee on Immunization Practices (ACIP) first recommended using a sequential IPV-OPV schedule to reduce the risk of VAPP in 1996 and then an all IPV schedule in 1999. Although OPV is no longer used in this country, the federal government maintains a stockpile of OPV to use for mass immunization if there is ever an outbreak of polio in this country.

OPV is used in countries where polio remains endemic or where the risk of importation is greater than the risk of VAPP.

In 1988, the World Health Assembly passed a resolution to eradicate polio. At that time, there were an estimated 350,000 cases of polio per year in over 125 countries. Today there are only three countries in which polio remains endemic; Afghanistan, Pakistan, and Nigeria.





Polio cases in the world in 2012
Afghanistan, Pakistan, and Nigeria are the last remaining polio-endemic countries. Last year, polio was imported from Nigeria to Chad and Niger, where transmission had been interrupted.
Global Polio Eradication Initiative


 
We are closer than ever to eradicating polio from the world forever.

Songwriters Robert and Richard Sherman wrote "A Spoonful of Sugar" for the 1964 movie Mary Poppins after Robert heard that his children had received oral polio vaccine on a sugar cube.

President Franklin Delano Roosevelt founded the National Foundation for Infantile Paralysis, now known as the March of Dimes Foundation, to fund polio vaccine research. The U.S. ten cent piece (dime) bears his image for this reason. Roosevelt contracted polio at the age of 39.

More information
Regina Edwards, 1952
March of Dimes
References

Centers for Disease Control and Prevention. (2000). Poliomyelitis prevention in the United States: updated recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report, 49(5), 1-22. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr4905a1.htm

Centers for Disease Control and Prevention. (2012). Epidemiology and prevention of vaccine-preventable diseases (12th Ed.). Washington D.C.: Public Health Foundation. http://www.cdc.gov/vaccines/pubs/pinkbook/polio.html

Malonado, Y. A. (2009). Polioviruses. In S. S. Long (Ed.) Principles and practice of pediatric infectious diseases (3rd Ed.) [Electronic version].

Modlin, J. F. (2009). Poliovirus. In Mandell, G. L., Bennett, J. E., & Dolin, R. (Eds.). Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. (7th Ed.) [Electronic version].

Offit, P. A. (2005). The Cutter incident: how America's first polio vaccine led to the growing vaccine crisis. New Haven: Yale University Press.

Plotkin, S. A. & Vidor, E. (2012). Poliovirus vaccine-inactivated. In S. A. Plotkin, W. A. Orenstein, & P. A. Offit (Eds.) Vaccines (6th Ed.). [Electronic version].

Sutter, R. W., Kew, O. M., & Cochi, S. L. (2012). Poliovirus vaccine-live. In S. A. Plotkin, W. A. Orenstein, & P. A. Offit (Eds.) Vaccines (6th Ed.). [Electronic version].

World Health Organization. (2013). Poliomyelitis fact sheet. http://www.who.int/mediacentre/factsheets/fs114/en.

Sunday, November 18, 2012

Malaria vaccines

I just returned from the annual meeting of the American Society of Tropical Medicine and Hygiene (ASTMH) where I attended symposia and scientific sessions on a number of topics including multidrug resistant tuberculosis, rabies, polio eradication, and child health. I also attended several presentations on malaria and dengue vaccines.

You may have heard about malaria vaccines in the news. The Bill and Melinda Gates Foundation has been funding malaria vaccine research and there have been some successes and some disappointing results reported in the news.

Although it's the American Society of Tropical Medicine and Hygiene, scientists from around the world come to ASTMH meetings to present their research. There are a number of malaria vaccines in various stages of development; some of them are in preclinical (animal) trials and some in clinical (human) trials. There are no malaria vaccines licensed or approved for use and none are available to the public.

Niger River, Mali 1988
Malaria is a disease with which I am fascinated and for which I have tremendous respect – it nearly killed me the second time I had it. I could spend several pages discussing malaria, but it's a complex disease with complex interactions between humans, mosquitoes, and the environment and, as much as I enjoy talking about malaria, I won't go into that level of detail here. I have included some links to webpages on malaria at the end of this post.


About half of the world's population lives in areas where malaria is transmitted. The World Health Organization estimates that there were about 216 million cases of malaria worldwide in 2011 and that around 655,000 malaria deaths in 2010, most of them children under five years of age in sub-Saharan Africa. Although that's down from over a million malaria deaths every year, some researchers believe that the annual number of malaria deaths is underestimated. That's not surprising considering that many of those deaths occur in rural areas of developing countries and are not reported to health authorities.


When I've mentioned that I've had malaria, people have said to me, "You must have drunk the water," "You must not have gotten the vaccine," or, "I heard that once you have it you have it for life," so it seems to me that there is some confusion about malaria – which doesn't surprise me.

Malaria is caused by a protozoan parasite which is transmitted through mosquito bites. Different species of Plasmodium infect humans, other mammals, birds, and reptiles. There a four species of human malaria: P. falciparum, P. malariae, P. ovale, and P. vivax. Humans can also be infected with P. knowlesi, a monkey malaria. P. ovale and P. vivax can cause relapses months to years after the first infection and people can have subclinical P. malariae infections for decades, but all of the species are curable, so "once infected, always infected" is not necessarily true.

Most malaria deaths and severe malaria infections are caused by P. falciparum. In addition to its severity and lethality, P. falciparum has developed resistance to almost every drug used to prevent and treat infection. For these reasons, most of the malaria vaccines that are in development are against P. falciparum.

The malaria parasite has several mechanisms by which it evades the human immune system. These create challenges for malaria vaccine developers. I will briefly discuss two of them:

Malaria lifecycle

The malaria parasite lifecycle includes several stages in both vertebrate and mosquito hosts. The parasite expresses different antigens at each stage of its lifecycle so that an immune response against one stage of the parasite will not "recognize" the parasite at a different stage.
 
 
Most cells in the body are able to signal cytotoxic lymphocytes that they are infected. These white blood cells can then kill the infected cell and the infecting agent along with it. The malaria parasite spends most of its time in the human body inside hepatocytes (liver cells) and erythrocytes (red blood cells), two types of cells that lack the ability to notify the immune system that they are infected with the parasite. The two extracellular (outside of cells) stages, sporozoites and merozoites, are present in the blood for a very short time, which limits their exposure to antibodies against them.

Immunity to malaria

Humans do not develop sterilizing immunity to malaria, that is, people who have been infected with malaria can have it again. The most effective immune responses are against proteins that are made by the parasite and expressed on the surface of infected red blood cells. The problem is, the parasite has genes that allow it to change those surface antigens and make infected cells unrecognizable to the immune system.

People who live in areas where malaria is transmitted develop a repertoire of antibodies against P. falciparum erythrocyte membrane protein 1 (PfEMP1). This keeps the number of infected blood cells low so that the person can be infected with the parasite but have relatively minor symptoms or no symptoms at all ("partial immunity").

People who live in endemic areas remain partially immune to malaria as long as they continue to be periodically infected with the parasite. Once a person is no longer exposed to malaria (e.g., moves someplace where malaria is not transmitted), she or he loses immunity and becomes susceptible to severe malaria again. A large proportion of cases of malaria in the U.S. are in people who came from malaria-endemic countries, lived in the U.S., and then returned to their country of origin to visit friends and relatives (VFR), thinking that they were still protected against malaria and did not need to take malaria prophylaxis.

Malaria vaccines



Mosquito injecting sporozoites
CDC
Researchers must choose a parasite antigen to which the human body will develop an adequate immune response. So far, the most successful vaccines have been against sporozoites, the infective stage of the parasite that is injected into the blood with mosquito saliva. Vaccines against other parasite stages have been developed, including transmission blocking vaccines which stimulate the immune system to produce antibodies that are ingested by the mosquito and prevent parasite development in the mosquito gut. These vaccines do not directly prevent human infection and disease but, theoretically, prevent transmission from an infected person to an uninfected person.
RTS,S is a sporozoite antigen vaccine in phase III trials which test how well the vaccine prevents disease in people who live in malaria endemic areas. Results of a study in African children 5 to 17 months of age and African infants 6 to 12 months of age (presented at the ASTMH meeting this year) demonstrated that RTS,S provides modest protection against malaria in children who received three doses of the vaccine.

While the press has called these results "disappointing" because the vaccine did not protect against malaria as well as had been hoped, these are positive results against an elusive pathogen. Even a modest reduction in malaria burden can save thousands of lives. I think it's also important to remember that current vaccines prevent bacterial and viral infections. This is the first vaccine against a protozoan pathogen.

Further RTS,S trials in different populations and using different dosing schedules are ongoing as are trials of other malaria vaccine candidates.


More information

References

Fairhurst, R. M. & Wellems, T. E. (2009). In G. L. Mandell, J. E. Bennett, & R. Dolin (Eds.) Mandell, Douglas, and Bennett's principles and practice of infectious diseases (7th ed.). Elsevier [Electronic version].

Holding, P. A., Snow, R. W. (2001). Impact of Plasmodium falciparum malaria on performance and learning: review of the evidence. American Journal of Tropical Medicine and Hygiene, 64(Suppl. 1), 68-75. http://www.ajtmh.org/content/64/1_suppl/68.abstract.

Murray, C. J., Rodenfeld, L. C., Lim, S. S., Andrews, K. G., Foremen, K. J., Haring, D. et al. (2012). Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet, 379(9814), 413-431. http://www.ncbi.nlm.nih.gov/pubmed/22305225.

Plebanski, M., & Hill, A. V. S. (2000). The immunology of malaria infection. Current Opinion in Immunology, 12(4), 437-441. http://www.ncbi.nlm.nih.gov/pubmed/10899022.

The RTS,S Clinical Trials Partnership. (2011). First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children. New England Journal of Medicine, 365(20), 1863-1875. http://www.nejm.org/doi/full/10.1056/NEJMoa1102287.

The RTS,S Clinical Trial Partnership. (2012). A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. New England Journal of Medicine [Epub ahead of print]. http://www.nejm.org/doi/full/10.1056/NEJMoa1208394.

Sachs, J. & Malaney, P. (2002). The economic and social burden of malaria. Nature, 415(6872), 680-685. http://www.ncbi.nlm.nih.gov/pubmed/11832956.

Yazdani, S. S., Mukherjee, P., Chauhan, V. S., & Chitnis, C. E. (2006). Immune responses to asexual blood-stages of malaria parasites. Current Molecular Medicine, 6(2), 187-203. http://www.ncbi.nlm.nih.gov/pubmed/16515510.

 

Thursday, November 1, 2012

Hepatitis B


Andrew received his first hepatitis B vaccine minutes after he was born. There are several reasons for starting the hepatitis B vaccine series at birth. To understand them, we first need to understand the epidemiology and natural history of hepatitis B virus (HBV) infection.

Andrew shortly after receiving his first dose of hepatitis B vaccine

Hepatitis B virus transmission
Like human immunodeficiency virus (HIV), HBV is transmitted through blood and body fluids. Unlike HIV, HBV can survive outside of the human body and remain infectious over a week. HBV is also 50 to 100 times more infectious than HIV.
Worldwide, most HBV infections are acquired perinatally; that is, the virus was passed from an infected mother during childbirth. Infants who become infected with HBV are much less likely to develop symptoms of acute hepatitis B and much more likely to develop chronic HBV infection than adults who acquire the infection.
Age at infection:
Acute hepatitis B
Risk
Under 5 years of age
<10%
Over 5 years of age
30% to 50%
Chronic HBV infection
 
Infants
90%
1 to 4 years of age
30%
Adults
<5%
Transmission of HBV also occurs among household contacts of people with HBV infection, through sexual contact, through injection drug use, and is an occupational risk for people with frequent contact with blood and/or body fluids (e.g., health care providers. I was required to take the hepatitis B vaccine series when I started nursing school). Although hepatitis B was called "serum hepatitis" because it was frequently transmitted through blood transfusions, blood is now screened for hepatitis and other pathogens, so there is an extremely low risk of HBV infection from receiving a blood transfusion.
Hepatitis B infection
In my previous post on hepatitis, I briefly described the symptoms of acute hepatitis: jaundice, fatigue, malaise, muscle and joint pain, nausea and vomiting, and pain over the liver. Although fulminant liver failure can occur as a result of infection with any of the hepatotropic viruses (hepatitis A, B, C, D, and E viruses), most people recover from acute hepatitis without serious consequences.
People with chronic HBV infection can be completely asymptomatic for decades. Chronic HBV infection increases the risk for liver cirrhosis and hepatocellular carcinoma (HCC, liver cancer). Babies can be infected at birth, show no signs of being infected, and then develop fatal liver disease later in childhood or as adults.
Hepatocellular carcinoma
CDC/Patricia Walker, M.D., Regions Hospital, MN
 
Cancer vaccine
Studies of hepatitis B vaccine have been ongoing since the 1980s. Vaccinating children against hepatitis B has reduced the incidence of HCC in children who received the vaccine in Taiwan, and Thailand and eliminated hepatitis B-associated HCC in Alaska Native children. For this reason, hepatitis B vaccine is considered the first cancer vaccine.
Vaccine safety
Hepatitis B vaccines contain a single viral surface antigen that is produced by yeast using recombinant DNA, similar to the way insulin (Humulin®, Novolin®) is made using yeast or the bacteria E. coli. Hepatitis B vaccines do not contain HBV and HBV is not used in the production of hepatitis B vaccines.
The safety of hepatitis B vaccines has been studied since the introduction of plasma-derived vaccines in the 1980s. The Institute of Medicine (IOM) has published two reviews of hepatitis B vaccine safety. The only adverse effect identified as causally associated with hepatitis B vaccines is a severe allergic reaction (anaphylaxis) in people who are allergic to yeast. This association was based on 10 cases of anaphylaxis in people who had received a hepatitis B vaccine. Another review of adverse reaction data found that hepatitis B vaccine-associated anaphylaxis in children is rare.
Why vaccinate babies against hepatitis B?
The most common way HBV is transmitted is from mother to child during childbirth. Babies who become infected with HBV are more likely to develop chronic HBV infection and less likely to have symptoms of acute hepatitis then older children and adults. Therefore, infancy is the most dangerous time to be infected with HBV. Immunizing babies against hepatitis B can prevent HBV infection and has been found to reduce the incidence of HCC in children.
The reason for universal immunization against hepatitis B can be found in the title of the Advisory Committee on Immunization Practices (ACIP) recommendations: A comprehensiveimmunization strategy to eliminate transmission of hepatitis B virus infection in the United States. I discussed disease eradication in and disease elimination previous posts. Disease elimination is "the reduction to zero of the incidence of infection caused by a specific agent in a defined geographical area as a result of deliberate efforts" (Dowdle, 1999); that is, transmission of the disease no longer occurs in a specific area of the world (in contrast to eradication, in which disease transmission no longer occurs anywhere in the world).
The study in Alaska demonstrated that HBV infection and HCC can be eliminated from a defined geographic region using universal childhood hepatitis B immunization. The incidence of HBV infection in children throughout the U.S. has decreased dramatically since the introduction of hepatitis B vaccines.


Mary 
Yesterday, the eve of All Saints Day, my mother-in-law Mary Esvelt died from a complication of the malignant brain tumor with which she was diagnosed on Mother's Day of this year.
I know of no person more dedicated to serving the Lord than Mary. She delighted in her ministries and teaching Christian belief and values.
I met the Esvelts while taking care of Seth, Holly's brother, who suffered a severe traumatic brain injury in a motor vehicle accident. Seth has remained in a minimally conscious state since the injury. Mary and Craig have cared for Seth at home 24/7 since Holly and I were married seven years ago.
Despite the physical pain she suffered from rheumatoid arthritis and the emotional pain of having a severely disabled son, Mary remained firm in her faith and tireless in her service to others. Mary was a blessing to all who knew her.
Of course, I admire Mary most for being the mother of my precious wife Holly.
"We do not want you to be unaware, brothers, about those who have fallen asleep, so that you may not grieve like the rest, who have no hope."
- 1 Thessalonians 4:13
References
Bohlke, K., Davis, R. L., Marcy, S. M., Braun, M. M., DeStefano, F., Black, S. B. et al. (2003). Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics, 112(4), 815-820. http://www.ncbi.nlm.nih.gov/pubmed/14523172.
Centers for Disease Control and Prevention. (2004). Incidence of acute hepatitis B – United States, 1990-2002. Morbidity and Mortality Weekly Report, 52(51 & 52), 1252-1254. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5251a3.htm.
Centers for Disease Control and Prevention. (2005). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Part 1: Immunization of infants, children, and adolescents. Morbidity and Mortality Weekly Report, 54(16), 1-23. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5416a1.htm.
Chang, M. H., You, S. L., Chen, C. J., Liu, C. J., Lee, C. M., Lin, S. M., et al. (2009). Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. Journal of the National Cancer Institute, 101(19), 1348-1355. http://jnci.oxfordjournals.org/content/101/19/1348.long.
Dowdle, W. R. (1999). The principles of disease elimination and eradication. Morbidity and Mortality Weekly Report, 48(Supple. 1), 23-27. http://www.cdc.gov/mmwr/preview/mmwrhtml/su48a7.htm.
Institute of Medicine. (2002). Hepatitis B vaccine and demyelinating neurological disorders. Washington D. C.: National Academies Press. http://books.nap.edu/catalog.php?record_id=10393.
Institute of Medicine. (2012). Adverse effects of vaccines: evidence and causality. Washington D.C.: National Academies Press. http://www.nap.edu/catalog.php?record_id=13164.
Kew, M. C. (2010). Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma. Pathologie Biologie, 58(4), 273-277. http://www.ncbi.nlm.nih.gov/pubmed/20378277.
Mast, E. E. & Ward, J. W. (2008). Hepatitis B vaccine. In S. A. Plotkin, W. A. Orenstein, & P. A. Offit (Eds.) Vaccines (5th Ed.) [Electronic version].
McMahon, B. J., Bulkow, L. R., Singleton, R. J., Williams, J., Snowball, M., Homan, C. et al. (2011). Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. Hepatology, 54(3), 801-807. http://www.ncbi.nlm.nih.gov/pubmed/21618565.
Ni, Y. H. & Chen, D. S. (2010). Hepatitis B vaccination in children: the Taiwan experience. Pathologie Biologie, 58(4), 296-300. http://www.ncbi.nlm.nih.gov/pubmed/20116181.
Park, N. H., Chung, Y. H., & Lee, H. S. (2010). Impacts of vaccination on hepatitis B viral infections in Korea over a 25-year period. Intervirology, 52(1), 20-28. http://www.ncbi.nlm.nih.gov/pubmed/20068337.
Tajiri H, Tanaka H, Brooks S & Takano T. (2011). Reduction of hepatocellular carcinoma in childhood after introduction of selective vaccination against hepatitis B virus for infants born to HBV carrier mothers. Cancer Causes & Control, 22(3), 523-7. http://www.ncbi.nlm.nih.gov/pubmed/21191808.
Viviani, S., Carrieri, P., Bah, E., Hall, A. J., Kirk, G. D., Mendy, M. et al. (2008) Gambia Hepatitis Intervention Study.20 years into the Gambia Hepatitis Intervention Study: assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer. Cancer Epidemi0ology, Biomarkers & Prevention, 17(11), 3216-3223. http://cebp.aacrjournals.org/content/17/11/3216.long.
Wasley, A., Kruszon-Moran, D., Kuhnert, W., Simard, E. P., Finelli, L., & Bell, B. (2010). The prevalence of hepatitis B virus infection in the United States in the era of vaccination. Journal of Infectious Diseases, 202(2),192-201. http://jid.oxfordjournals.org/content/202/2/192.long.
Wichajarn, K., Kosalaraksa, P., & Wiangnon, S. (2008). Incidence of hepatocellular carcinoma in children in Khon Kaen before and after national hepatitis B vaccine program. Asian Pacific Journal of Cancer Prevention, 9(3), 507-509 http://www.apocp.org/cancer_download/Volume9_No3/507%20Wichajarn%20.pdf.